Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD and Actelion deal reaches fourth milestone

MSD and Actelion deal reaches fourth milestone

10th December 2007

Actelion has announced that, together with with Merck, Sharp and Dohme (MSD), it has begun dosing for the phase II clinical programme for their new renin inhibitor, with this action marking the fourth milestone for the companies’ partnership.

The reaching of this landmark has triggered a milestone payment by MSD to Actelion for the total sum of $10 million (4.93 million pounds).

MSD and Actelion signed a worldwide partnership agreement for the discovery, development and commercialisation of novel classes of orally-available renin inhibitors for patients with cardio-renal diseases in December 2003.

Development of compounds manufactured through this collaboration is conducted by a joint committee of both companies.

Jean-Paul Clozel, chief executive officer of Actelion, said: “Actelion and Merck have worked closely to advance our common understanding about what is needed to realise the full potential of renin inhibition in cardiovascular disease.”

He added that he is very pleased about the progress seen by the collaboration over the past four years.

Last month, Actelion announced the appointment of Otto Schwarz as the new head of business operations at the firm, with Mr Schwarz replacing Christian Chavy in the role from January 14th 2008.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.